Mather Group LLC. grew its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 44.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 13,156 shares of the company’s stock after buying an additional 4,024 shares during the quarter. Mather Group LLC.’s holdings in Eli Lilly and Company were worth $15,223,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in Eli Lilly and Company in the fourth quarter worth $39,000. Finally, Aventus Investment Advisors Inc. grew its stake in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Trading Up 3.8%
NYSE:LLY opened at $1,211.08 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.14 trillion, a PE ratio of 40.64, a price-to-earnings-growth ratio of 1.50 and a beta of 0.46. The firm’s 50 day moving average is $1,177.42 and its 200 day moving average is $1,104.28. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65.
Analyst Upgrades and Downgrades
LLY has been the subject of a number of recent analyst reports. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Berenberg Bank set a $1,400.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.
View Our Latest Stock Analysis on LLY
Insider Activity
In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last 90 days. Insiders own 0.14% of the company’s stock.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Analysts at Erste Group raised their FY2026 EPS estimate to $36.55 from $36.45 and their FY2027 forecast to $47.30 from $47.18, reinforcing expectations for continued profit growth above consensus. Analyst earnings estimates
- Positive Sentiment: Investor commentary continues to highlight Lilly’s dominant position in diabetes and obesity treatments, strong revenue growth and a pipeline that could support further expansion beyond Zepbound. Retatrutide is viewed as a particularly important future growth opportunity ahead of the company’s October 29 earnings report. Retatrutide earnings outlook
- Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to test the experimental breast-cancer drug PRT13722 in combination with established therapies. Enrollment is expected to begin in the fourth quarter, adding potential long-term oncology value to Lilly’s pipeline. Prelude and Lilly breast cancer collaboration
- Positive Sentiment: Broader oncology spending is projected to exceed $400 billion globally by 2028, creating an attractive market backdrop for Lilly’s cancer-drug development and partnerships. Cancer drug spending outlook
- Neutral Sentiment: A Phase 1 food-effect study for tersolisib represents incremental pipeline progress, but the early-stage trial is unlikely to materially affect near-term earnings or valuation. Tersolisib study update
- Negative Sentiment: Valuation remains a concern after a roughly 404% five-year rally. Lilly trades at a high earnings multiple, so the stock may need sustained obesity-drug growth and successful pipeline launches to justify its price. Investors also face near-term volatility around the upcoming earnings release and clinical data.
- Negative Sentiment: A combination treatment generated greater weight loss than Zepbound in reported findings, but discontinuation rates were substantially higher, highlighting potential tolerability and adherence challenges for next-generation obesity therapies. Obesity-drug combination results
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.
Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
